{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:48:58Z","timestamp":1794282538793,"version":"4.9.0"},"reference-count":30,"publisher":"Massachusetts Medical Society","issue":"2","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100016957","name":"Mirati Therapeutics, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016957","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2022,7,14]]},"DOI":"10.1056\/nejmoa2204619","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T14:00:13Z","timestamp":1654264813000},"page":"120-131","source":"Crossref","is-referenced-by-count":1057,"title":["Adagrasib in Non\u2013Small-Cell Lung Cancer Harboring a\n                    <i>\n                      KRAS\n                      <sup>G12C<\/sup>\n                    <\/i>\n                    Mutation"],"prefix":"10.1056","volume":"387","author":[{"given":"Pasi A.","family":"J\u00e4nne","sequence":"first","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Riely","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca S.","family":"Heist","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong I.","family":"Ou","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Pacheco","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Johnson","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua K.","family":"Sabari","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Yau","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8764-4359","authenticated-orcid":false,"given":"Lyudmila","family":"Bazhenova","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6699","authenticated-orcid":false,"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan A.","family":"Pennell","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenna","family":"Anderes","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirak","family":"Der-Torossian","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Velastegui","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yan","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Christensen","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Chao","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander I.","family":"Spira","sequence":"additional","affiliation":[{"name":"From the Lowe Center for Thoracic Oncology, Dana\u2013Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) \u2014 both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) \u2014 all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.),  the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) \u2014 all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2019.03.002"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.120858"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030638"},{"key":"e_1_3_5_5_2","doi-asserted-by":"crossref","unstructured":"Salem M El-Refai S Sha W et al. Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignancies. In: Proceedings and Abstracts of the 2021 Annual Meeting of the European Society for Medical Oncology September 16\u201321 2021. Lugano Switzerland: European Society for Medical Oncology 2021. abstract.","DOI":"10.1016\/j.annonc.2021.05.007"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02752"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.02.005"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.05.026"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4023"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1167"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad6204"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12796"},{"key":"e_1_3_5_13_2","unstructured":"Food and Drug Administration. FDA approves first targeted therapy for lung cancer mutation previously considered resistant to drug therapy. May 28 2021 (https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug)."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13010151"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1884-x"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02052"},{"key":"e_1_3_5_17_2","doi-asserted-by":"crossref","unstructured":"J\u00e4nne PA Rybkin I Spira A et al. KRYSTAL-1: updated safety and efficacy data with adagrasib (MRTX849) in NSCLC with KRASG12C mutation from a phase 1\/2 study. In: Proceedings and Abstracts of the 32nd Annual EORTC-NCI-AACR Symposium October 24\u201325 2020. Brussels: European Organisation for Research and Treatment of Cancer 2020. abstract","DOI":"10.1016\/S0959-8049(20)31076-5"},{"key":"e_1_3_5_18_2","doi-asserted-by":"crossref","unstructured":"Bekaii-Saab TS Spira A Yaeger R et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. In: Proceedings and Abstracts of the 2022 ASCO Gastrointestinal Cancers Symposium January 20\u201322 2022. San Francisco: American Society of Clinical Oncology 2022. abstract.","DOI":"10.1200\/JCO.2022.40.4_suppl.519"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(20)31077-7"},{"key":"e_1_3_5_20_2","doi-asserted-by":"crossref","unstructured":"Weiss J Yaeger R Johnson ML et al. KRYSTAL-1: adagrasib (MRTX849) as monotherapy of in combination with cetuximab in patients with colorectal cancer harboring a KRASG12C mutation. In: Proceedings and Abstracts of the 2021 Annual Meeting of the European Society of Medical Oncology 2021. September 16\u201321 2021. Lugano Switzerland: European Society for Medical Oncology. abstract.","DOI":"10.1016\/j.annonc.2021.08.2093"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0383"},{"key":"e_1_3_5_22_2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). November 9 2016 (https:\/\/database.ich.org\/sites\/default\/files\/E6_R2_Addendum.pdf)."},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60845-X"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.06.001"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103695"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.06.030"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13143572"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.122"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.08.547"},{"key":"e_1_3_5_31_2","unstructured":"Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics\u2019 new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https:\/\/ir.mirati.com\/press-releases\/press-release-details\/2022\/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer\/default.aspx)."}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2204619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T19:11:26Z","timestamp":1749669086000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2204619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,7,14]]}},"alternative-id":["10.1056\/NEJMoa2204619"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2204619","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]}}}